TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Tyler Van Buren

Managing Director, Health Care - Biotechnology

Headshot photo of Tyler Van Buren

Tyler Van Buren is a Managing Director and senior equity research analyst on the biotechnology team at TD Cowen.

Mr. Van Buren has a decade and a half of equity research experience and is responsible for providing analysis on large-, mid-, and small-cap biotechnology stocks. His views on biotechnology topics are often quoted by national news services such as Bloomberg, Endpoints News, Reuters, STAT, and the Wall Street Journal, and he has been featured as a guest on CNBC and Fox News.

Prior to rejoining TD Cowen, Mr. Van Buren was a Managing Director and senior biotechnology equity research analyst at Piper Sandler (previously Piper Jaffray) for over three years. Prior to Piper Sandler, Mr. Van Buren spent five years on the biopharma research team at TD Cowen. Previously, Van Buren was a founding member and Managing Director at LifeSci Advisors where he helped build the firm’s biotechnology research practice. Earlier in his career, he worked at Amylin Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham Medical Research Institute, and the U.S. Department of Agriculture.

Mr. Van Buren earned a master’s degree in biology and a bachelor’s degree in biochemistry and cellular biology from the University of California, San Diego.


Get In Touch

Start a conversation with Tyler Van Buren


    Explore related thought leadership, reports, coverage and insights for Tyler Van Buren.

    A chemist in a lab is taking precaution as he conducts research in full protective gear towards the end of biodefense.
    Ahead of the Curve®

    A New Chapter In Biosecurity: Are We Prepared?

    Medical researcher conducting pharmaceutical research in a lab. Representing innovative therapies for fighting cancer i.e., immuno-oncology
    Ahead of the Curve®

    Investors Guide to Immuno-Oncology

    A view of a blood sample under a microscope
    Ahead of the Curve®

    MRD 2.0: Deep Dive Into The Coming Solid Tumor Opportunity